CytRx Faces Nasdaq Delisting Hearing

genomeweb
360dx

CytRx Faces Nasdaq Delisting Hearing

Apr 28, 2004

NEW YORK, April 28 (GenomeWeb News) - CytRx faces a May 13 hearing before the Nasdaq Qualifications Panel over a possible delisting of the company's common stock from the Nasdaq Small Cap market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

In Brief This Week: Novogene, Hologic, Agilent, Diagenode
Spontaneous Preterm Birth Clues Identified in Cervicovaginal Microbiome
Germany Plans Limited Coverage of NIPT for High-Risk Pregnancies
Bruker TB Test, PCR Platform Receives CE-IVD Mark
Single-Cell Sperm Sequencing Reveals New Details About Recombination
New Products Posted to GenomeWeb: Roche Diagnostics, Asuragen, Mission Bio

The Scan

Concerns About Bias in Policies

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Reprogrammable DNA

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Lack of Diversity

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

This Week in Science

In Science this week: whole-genome sequencing of single sperm cells, and more.

Menu